Trio Medicines Ltd.

🇬🇧United Kingdom
Ownership
Private
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin

First Posted Date
2015-12-03
Last Posted Date
2015-12-03
Lead Sponsor
Trio Medicines Ltd.
Target Recruit Count
48
Registration Number
NCT02620696

YF476 in Barrett's Esophagus

Phase 2
Completed
Conditions
Barrett's Esophagus
Interventions
Drug: YF476
Drug: YF476 placebo
First Posted Date
2015-11-05
Last Posted Date
2021-04-12
Lead Sponsor
Trio Medicines Ltd.
Target Recruit Count
27
Registration Number
NCT02597712
Locations
🇺🇸

Columbia University, Division of Digestive & Liver Diseases, New York, New York, United States

🇬🇧

MRC Cancer Unit, University of Cambridge, Cambridge, Cambridgeshire, United Kingdom

YF476 and Type II Gastric Carcinoids

Phase 2
Terminated
Conditions
Zollinger-Ellison Syndrome
Interventions
Drug: YF476
First Posted Date
2015-05-27
Last Posted Date
2021-01-29
Lead Sponsor
Trio Medicines Ltd.
Target Recruit Count
3
Registration Number
NCT02454075

Avonex®: Safety, Blood Levels and Effects

Phase 1
Completed
Conditions
Multiple Sclerosis (MS)
First Posted Date
2013-05-27
Last Posted Date
2013-05-27
Lead Sponsor
Trio Medicines Ltd.
Target Recruit Count
77
Registration Number
NCT01863069
Locations
🇬🇧

Hammersmith Medicines Research, London, United Kingdom

Effects of YF476 and Rabeprazole on Gastric Function

Phase 1
Completed
Conditions
Hypergastrinaemia
First Posted Date
2012-10-03
Last Posted Date
2012-10-03
Lead Sponsor
Trio Medicines Ltd.
Target Recruit Count
32
Registration Number
NCT01699113
Locations
🇬🇧

Hammersmith Medicines Research, London, United Kingdom

Effect of Single Doses of YF476 on Stomach Acidity

Phase 1
Completed
Conditions
Hypergastrinaemia
First Posted Date
2012-05-18
Last Posted Date
2012-05-18
Lead Sponsor
Trio Medicines Ltd.
Target Recruit Count
12
Registration Number
NCT01601418
Locations
🇬🇧

Hammersmith Medicines Research, London, United Kingdom

Effect of Repeated Doses of YF476 on Stomach Acidity

Phase 1
Completed
Conditions
Hypergastrinaemia
First Posted Date
2012-05-18
Last Posted Date
2012-05-18
Lead Sponsor
Trio Medicines Ltd.
Target Recruit Count
10
Registration Number
NCT01601405
Locations
🇬🇧

Hammersmith Medicines Research, London, United Kingdom

Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers

Phase 1
Completed
Conditions
Reflux Oesophagitis
First Posted Date
2012-05-16
Last Posted Date
2012-05-16
Lead Sponsor
Trio Medicines Ltd.
Target Recruit Count
49
Registration Number
NCT01599858
Locations
🇬🇧

Hammersmith Medicines Research, London, United Kingdom

Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers

Phase 1
Completed
Conditions
Reflux Oesophagitis
First Posted Date
2012-05-14
Last Posted Date
2012-05-14
Lead Sponsor
Trio Medicines Ltd.
Target Recruit Count
49
Registration Number
NCT01597674
Locations
🇬🇧

Hammersmith Medicines Research, London, United Kingdom

Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men

Phase 1
Completed
Conditions
Reflux Oesophagitis
First Posted Date
2012-02-24
Last Posted Date
2012-02-24
Lead Sponsor
Trio Medicines Ltd.
Target Recruit Count
15
Registration Number
NCT01538784
Locations
🇬🇧

Hammersmith Medicines Research, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy